Meeting News Coverage

New psoriasis treatments focus of AAD late-breaking research session

ORLANDO, Fla. —The efficacy and safety of new treatments for psoriasis were the focus of a late-breaking research session at the American Academy of Dermatology Annual Meeting.

“The [psoriasis] treatments continue to get better over time,” Joel M. Gelfand, MD, MSCE, FAAD, associate professor of dermatology and epidemiology at the University of Pennsylvania, who was the session co-moderator, told Healio.com/Dermatology. “We have excellent response rates already and the newer treatments are offering more rapid responses as well as higher response rates than we previously thought imaginable, so that is progress.

“Still, the challenge for patients is long-term control and so, these new emerging therapies that have higher efficacy than our prior treatments are unlikely to replace them, and they’re likely to augment them, because patients still need lots of mechanisms of actions to be available to them.”

Research presented on psoriasis included:

TNF-alpha antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study, presented by Robert Bissonnette, MD, MSc, FAAD.

A look at two, 16-week, phase 3, multicenter, randomized placebo-controlled trials of Cimzia (certolizumab pegol, UCB) treatment for plaque psoriasis by Alice B. Gottlieb, MD, PhD, FAAD.

Certolizumab pegol is currently approved for treating psoriatic arthritis but not psoriasis.

“Certolizumab pegol will likely offer us another excellent TNF-inhibitor in our treatment armamentarium for people with psoriasis and that’s going to be important because we know that our patients lose response in these classes of agents, and having a third subcutaneous one available will be a nice improvement in clinical practice,” Gelfand said.

The efficacy of Taltz (ixekizumab, Eli Lilly and Company) compared with Stelara (ustekinumab, Janssen) after 24 weeks of treatment in patients with moderate to severe plaque psoriasis in a head-to-head trial by Kristian D. J. Reich, MD, PhD.

A dose-finding study of SSK2894512 cream for treating plaque psoriasis by Tomoko Maeda-Churbachi, MD, PhD, MBA.

Efficacy and safety of topical 1% benvitimod cream for treating mild-to-moderate plaque psoriasis by Jianzhong Zhang, MD.

Other research presented in the session included new treatment options for atopic dermatitis and genital warts. – by Bruce Thiel

Reference:

F056. Late-breaking research: Clinical trials. Presented at: American Academy of Dermatology Annual Meeting; March 3-7, Orlando.

Disclosure: Healio.com/Dermatology was unable to determine relevant financial disclosures at time of publication.

ORLANDO, Fla. —The efficacy and safety of new treatments for psoriasis were the focus of a late-breaking research session at the American Academy of Dermatology Annual Meeting.

“The [psoriasis] treatments continue to get better over time,” Joel M. Gelfand, MD, MSCE, FAAD, associate professor of dermatology and epidemiology at the University of Pennsylvania, who was the session co-moderator, told Healio.com/Dermatology. “We have excellent response rates already and the newer treatments are offering more rapid responses as well as higher response rates than we previously thought imaginable, so that is progress.

“Still, the challenge for patients is long-term control and so, these new emerging therapies that have higher efficacy than our prior treatments are unlikely to replace them, and they’re likely to augment them, because patients still need lots of mechanisms of actions to be available to them.”

Research presented on psoriasis included:

TNF-alpha antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study, presented by Robert Bissonnette, MD, MSc, FAAD.

A look at two, 16-week, phase 3, multicenter, randomized placebo-controlled trials of Cimzia (certolizumab pegol, UCB) treatment for plaque psoriasis by Alice B. Gottlieb, MD, PhD, FAAD.

Certolizumab pegol is currently approved for treating psoriatic arthritis but not psoriasis.

“Certolizumab pegol will likely offer us another excellent TNF-inhibitor in our treatment armamentarium for people with psoriasis and that’s going to be important because we know that our patients lose response in these classes of agents, and having a third subcutaneous one available will be a nice improvement in clinical practice,” Gelfand said.

The efficacy of Taltz (ixekizumab, Eli Lilly and Company) compared with Stelara (ustekinumab, Janssen) after 24 weeks of treatment in patients with moderate to severe plaque psoriasis in a head-to-head trial by Kristian D. J. Reich, MD, PhD.

A dose-finding study of SSK2894512 cream for treating plaque psoriasis by Tomoko Maeda-Churbachi, MD, PhD, MBA.

Efficacy and safety of topical 1% benvitimod cream for treating mild-to-moderate plaque psoriasis by Jianzhong Zhang, MD.

Other research presented in the session included new treatment options for atopic dermatitis and genital warts. – by Bruce Thiel

Reference:

F056. Late-breaking research: Clinical trials. Presented at: American Academy of Dermatology Annual Meeting; March 3-7, Orlando.

Disclosure: Healio.com/Dermatology was unable to determine relevant financial disclosures at time of publication.

    See more from American Academy of Dermatology Meeting